Show simple item record

dc.contributor.authorFallon, SJ
dc.contributor.authorPlant, O
dc.contributor.authorTabi, YA
dc.contributor.authorManohar, SG
dc.contributor.authorHusain, M
dc.date.accessioned2023-08-01T15:08:35Z
dc.date.available2023-08-01T15:08:35Z
dc.date.issued2023-07-01
dc.identifier.issn2632-1297
dc.identifier.issn2632-1297
dc.identifier.otherARTN fcad207
dc.identifier.urihttps://pearl.plymouth.ac.uk/handle/10026.1/21123
dc.description.abstract

Cholinesterase inhibitors are frequently used to treat cognitive symptoms in Lewy body dementias (Parkinson’s disease dementia and Dementia with Lewy bodies). However, the selectivity of their effects remains unclear. In a novel rivastigmine-withdrawal design, Parkinson’s disease dementia and Dementia with Lewy bodies patients were tested twice: once when taking rivastigmine as usual and once when they had missed one dose. In each session, they performed a suite of tasks (sustained attention, simple short-term recall, distractor resistance and manipulating the focus of attention) which allowed us to investigate the cognitive mechanisms through which rivastigmine affects attentional control. Consistent with previous literature, rivastigmine withdrawal significantly impaired attentional efficacy (quicker response latencies without a change in accuracy). However, it had no effects on cognitive control as assessed by the ability to withhold a response (inhibitory control). Worse short-term memory performance was also observed when patients were OFF rivastigmine, but these effects were delay and load-independent, likely due to impaired visual attention. In contrast to previous studies that have examined the effects of dopamine withdrawal, cognitively complex tasks requiring control over the contents of working memory (ignoring, updating or shifting the focus of attention) were not significantly impaired by rivastigmine withdrawal. Cumulatively, these data support the conclusion cholinesterase inhibition has relatively specific and circumscribed – rather than global – effects on attention that may also affect performance on simple short-term memory tasks, but not when cognitive control over working memory is required. The results also indicate that withdrawal of a single dose of rivastigmine is sufficient to reveal these impairments, demonstrating that cholinergic withdrawal can be an informative clinical as well as an investigative tool.

dc.format.extentfcad207-
dc.format.mediumElectronic-eCollection
dc.languageen
dc.publisherOxford University Press (OUP)
dc.subjectLewy body dementias
dc.subjectsustained attention
dc.subjectworking memory
dc.subjectacetylcholine
dc.subjectcholinesterase inhibitors
dc.titleEffects of cholinesterase inhibition on attention and working memory in Lewy body dementias
dc.typejournal-article
dc.typeArticle
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/37545547
plymouth.issue4
plymouth.volume5
plymouth.publisher-urlhttp://dx.doi.org/10.1093/braincomms/fcad207
plymouth.publication-statusPublished
plymouth.journalBrain Communications
dc.identifier.doi10.1093/braincomms/fcad207
plymouth.organisational-group|Plymouth
plymouth.organisational-group|Plymouth|Faculty of Health
plymouth.organisational-group|Plymouth|Faculty of Health|School of Psychology
plymouth.organisational-group|Plymouth|REF 2021 Researchers by UoA
plymouth.organisational-group|Plymouth|Users by role
plymouth.organisational-group|Plymouth|Users by role|Academics
plymouth.organisational-group|Plymouth|REF 2021 Researchers by UoA|UoA04 Psychology, Psychiatry and Neuroscience
dc.publisher.placeEngland
dcterms.dateAccepted2023-06-01
dc.date.updated2023-08-01T15:08:24Z
dc.rights.embargodate2023-8-2
dc.identifier.eissn2632-1297
dc.rights.embargoperiodforever
rioxxterms.versionofrecord10.1093/braincomms/fcad207


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV